Osocimab (Anti-F11 / Factor XI) is an antibody targeting Factor FXI. FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects. MW: 145.5 KD.